Patients and Doctors Push Back Against the Harsh Side Effects of Cancer Drugs

— “If the patients are not taking the drug, then it’s not going to work”

February 6, 2024 10:30 am

By Associated Press.

For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary.

They’ve ignited a movement to radically change … Read more

Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC

A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.

January 30, 2024 9:00 am

Clearity’s Perspective: Most drugs are tested and approved to treat cancers based on where in the body the cancer started and the type of tissue from which it developed. Enhertu (Trastuzumab Deruxtecan, T-Dxd), a HER2-targeted antibody drug conjugate (ADC), already Read more

Lack of resource ‘equality’ means research of the deadliest cancers is often underfunded

January 26, 2024 9:00 am

By Josh Friedman

Key takeaways:

  • Breast cancer received 25% of cancer funding from 2015 to 2018.
  • Cancers with high mortality rates, such as colorectal and pancreatic cancer, are underfunded.

Cancer research and advocacy funding disproportionately skewed toward certain subtypes, leaving … Read more

Real-World Data Confirm the Incidence of ADC-Related Ocular Toxicities in Ovarian Cancer

January 26, 2024 9:00 am

By Ashling Wahner

Although the antibody-drug conjugate (ADC) mirvetuximab soravtansine-gynx (Elahere) is associated with a high rate of ocular toxicity in patients with folate receptor α (FRα)-positive, platinum-resistant ovarian cancer, the real-world incidence of this adverse effect (AE) in this … Read more

NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

January 19, 2024 9:00 am

Clearity’s Perspective: In the January 17, 2024 update to the National Comprehensive Cancer Network (NCCN) guidelines for ovarian cancer, several new therapies have been added to the list of acceptable regimens for recurrent platinum-resistant ovarian cancer. For example, trastuzumab deruxtecan Read more

Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy

January 11, 2024 9:00 am

Clearity offers emotional support to people diagnosed with ovarian cancer and their caregivers through our Steps Through OC program. If you would like personalized, one-to-one assistance with navigating the impact of an ovarian cancer diagnosis, our team of OC Counselors Read more

Gynecologic cancer clinical trial enrollment lower for certain underrepresented groups

December 29, 2023 9:00 am

By Erin T. Welsh, MA

Key takeaways:

  • Clinical trial enrollment was lower for Asian, Black and Hispanic women vs. white women.
  • Asian and Hispanic women were underrepresented in endometrial, cervical and ovarian cancer trials.

Asian, Black and Hispanic women with … Read more

Trial Analyzing MEK Inhibitor Combo for Ovarian Cancer Subset Begins

December 21, 2023 9:00 am

By Ashley Chan

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

A phase 3 trial analyzing the treatment combination of avutometinib and defactinib compared with … Read more

Psilocybin May Help Ease Depression in Cancer Patients

In small trial, half had early remission of depressive symptoms after psilocybin-assisted therapy

December 18, 2023 9:00 am

By Diana Swift

Psilocybin-assisted therapy in a group setting was safe and appeared effective in patients with cancer and depression, according to a small, phase II, open‐label trial.

After one dose of psilocybin among 30 patients, depression severity scores dropped … Read more

Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer

December 15, 2023 9:00 am

By Edward Winstead

For people being treated for cancer, participating in virtual mind–body fitness classes may have important benefits, such as reducing the risk of being hospitalized for treatment-related problems, according to results from a clinical trial.

In the trial, … Read more

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

December 6, 2023 9:00 am

By James H. Doroshow, M.D.

More than 8 years ago, NCI launched NCI-MATCH, a first-of-its-kind precision medicine cancer clinical trial. NCI-MATCH tested different targeted therapies in people with cancer whose tumors had specific genetic changes. This year, three second-generation precision

Read more

Ovarian Cancer Detected Early With DNA From Pap Smear in Proof-of-Principle Study

December 6, 2023 9:00 am

By Andrea Anderson

NEW YORK – An Italian team led by investigators at Humanitas University has come up with a test for detecting early-stage high-grade serous ovarian cancer (HGSOC) that relies on DNA sequencing of cervical smear samples collected during … Read more

From diagnosis through survivorship: Mindfulness can help people cope with cancer

Research has shown mindful meditation can reduce stress, relieve pain.

November 29, 2023 9:00 am

Clearity offers psychosocial support to caregivers through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with caring for a loved one with an ovarian cancer diagnosis, our team of OC Read more

PC14586 Targets Previously “Undruggable” p53 in Treatment of Solid Tumors

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.

November 27, 2023 9:00 am

By Kyle Doherty

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity. With the initiation of the phase … Read more

Artificial Intelligence May Predict Ovarian Cancer Therapy Outcomes

November 21, 2023 9:00 am

By Rylan DeStefano

An artificial intelligence model called IRON (Integrated Radiogenomics for Ovarian Neoadjuvant therapy) shows an 80% accuracy rate in the prediction of therapy outcomes for patients with ovarian cancer. The artificial intelligence model focuses specifically on the volumetric … Read more

Raludotatug Deruxtecan Elicits Early Efficacy and Safety in Platinum-Resistant Ovarian Cancer

November 17, 2023 9:00 am

Clearity’s Perspective: A phase I clinical trial studying the antibody-drug conjugate (ADC) raludotatug deruxtecan (DS-6000a, R-DXd) shows early encouraging activity in heavily pretreated ovarian cancer. The antibody portion of raludotatug deruxtecan targets CDH6 (found in about 65-85% of ovarian cancers) Read more

Scientists Piece Together DNA Repair Pathway Implicated in Breast, Ovarian, and Prostate Cancers

November 15, 2023 9:00 am

Clearity’s Perspective: Cancer cells that have mutations in BRCA or that are HRD-positive are not able to use the so-called homologous recombination repair pathway to fix mistakes in the cancer cell. These cancer cells become reliant on other repair pathways. Read more

Claudine Isaacs, MD, on the Limitations of At-Home Genetic Tests for Hereditary Breast/Ovarian Cancers

More than 95% of BRCA1 or BRCA1 pathogenic variants would have been missed by DTC testing, largest such study showed

November 8, 2023 9:00 am

By Mark Fuerst

Direct-to-consumer (DTC) genetic testing has limited use as a screening tool for identifying individuals at risk of hereditary breast or ovarian cancer, especially in those of non-Ashkenazi Jewish descent, researchers reported.

Most current DTC genetic tests evaluate … Read more

T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancers

November 7, 2023 9:00 am

RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer

November 5, 2023 9:00 am

Clearity’s Perspective: The combination of avutometinib and defactinib has shown encouraging activity in Low-Grade Serous Ovarian Cancer. Updated results from the RAMP 201 trial suggest that the combination is active regardless of the number of prior therapies patients have received. Read more